SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Nuvectis Pharma presents positive NXP200 Phase 1b results

The company provided highlights from an oral presentation of expanded data from the Phase 1b study.

NVCT

Related stories